Eisai Pharmaceutical Marketing Subsidiary in Singapore Launches Operations.
Previously, Eisai's pharmaceutical import and marketing business in Singapore was handled by Eisai Asia Regional Services Pte. Ltd. (EARS; Head office: Singapore; President: Hiroshi Kimura), but EARS has recently transferred this business to ESN.
By launching operations with this new company, Eisai aims to strengthen its pharmaceutical business in Singapore and further contribute to patients' value in the region.
EARS will renew its operation as a holding company assuming specific function of the seven local subsidiaries in the Asian region, including this newly established ESN in Singapore and existing six others in China, Thailand, Malaysia, the Philippines, Hong Kong and India.
Profile of Eisai (Singapore) Pte. Ltd.
Capital: 300,000 Singapore dollars (approx. 22,000,000 yen) Location: Singapore President: Celine Ting Scope of Business: Import, marketing, and promotion of pharmaceuticals Capital Alliance: 100% subsidiary of EARS
About Eisai Co., Ltd.
Eisai Co., Ltd. (TSE: 4523)(OTC: ESALY) is a research-based human health care company that discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 8,000 people worldwide. For more information, please visit http://www.eisai.co.jp.
Source: Eisai Co., Ltd.
Eisai Co., Ltd. Corporate Communications Department +81-3-3817-5120
Copyright [c] 2006 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K.
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 4, 2006|
|Previous Article:||Toyota to Enter Hybrid Sedan in 24-hour Race.|
|Next Article:||Kobe Steel to Start Indonesian Trial Project to Upgrade Brown Coal into High-rank Coal; Project to be Carried Out Under the Japan Coal Energy Center.|